Intangible Assets and Royalty Agreement (Details) (USD $)	3 Months Ended			0 Months Ended
	Mar. 31, 2015		Mar. 31, 2014	Jan. 29, 2007	Dec. 31, 2014		Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]
Total	$ 14,977,000				$ 14,776,000
Less Accumulated amortization	(4,164,000)				(3,931,000)
Net	10,813,000				10,845,000
Net book value	9,805,000
Amortization of intangible assets	233,000		231,000
Estimated future amortization expense [Abstract]
2015	697,000	[1]
2016	929,000
2017	840,000
2018	830,000
2019	830,000
Thereafter	5,679,000
Net book value	9,805,000
Licenses
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	10 years	[2],[3]
Gross Carrying Value	1,009,000	[2],[3]			1,009,000	[2],[3]
Licenses | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Finite-Lived Intangible Assets [Line Items]
Acquisition price				996,000
Maximum time of approval				30 days
Contingent payments to licensor	200,000
Contingent royalty to be paid to licensor (in hundredths)	3.00%
Annual royalty payment				50,000
Net book value	184,000
Estimated future amortization expense [Abstract]
Net book value	184,000
Licenses | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							13,000
Patents & Know How
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	17 years	[2]
Gross Carrying Value	7,893,000	[2]			7,891,000	[2]
Patents & Know How | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							7,690,000
Finite-Lived Intangible Assets, Costs	2,333
Customer & Supplier Relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Lives	14 years	[2]
Gross Carrying Value	3,761,000	[2]			3,761,000	[2]
Customer & Supplier Relationships | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value							3,761,000
Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	1,008,000	[2]			1,008,000	[2]
Tradenames & Trademarks | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived							1,008,000
In Process Research & Development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	25,000	[2]			25,000	[2]
In Process Research & Development | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived							25,000
Patents in Process
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value, Indefinite Lived	$ 1,281,000	[4]			$ 1,082,000	[4]

[1] Estimated amortization expense for the year ending December 31, 2015, includes only amortization to be recorded after March 31, 2015.

[2] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Trade Names & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2015 an additional $2,333 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.

[3] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license. As of March 31, 2015, this license had a remaining net book value of approximately $184,000

[4] Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.